Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry

Background: Previous studies and case-series showed improvement in left ventricular (LV) function and reverse remodeling after sacubitril/valsartan therapy in real-world studies. We therefore aimed to evaluate whether also right ventricular (RV) function may improve after sacubitril/valsartan therapy. Methods: Sixty consecutive patients with chronic heart failure and NYHA class II-Ill were followed up for 12 months after therapy with sacubitril/valsartan. Left and (RV) function was assessed at baseline and after 12 months of therapy. Results: At 12-month control, therapy with sacubitril/valsartan was associated with a significant improvement in a series of echo parameters: LVEF (p < 0.05), LV end-systolic volume (p < 0.01), left atrium area (p < 0.05). Right ventricular echo parameters were also improved after sacubitril/valsartan therapy: PAsP (31.0 +/- 12.8 vs 34.7 +/- 12.5 mmHg, p < 0.05), TAPSE (17.8 +/- 3.9 vs 16.5 +/- 4.0 mm, p < 0.001); mean PAsP reduction was 3.7 +/- 11.4 mmHg (-6.3 +/- 37.7%), mean TAPSE increase 1.3 +/- 2.5 mm (+9.5 +/- 15.7%). Indexed (%) improvement in PAsP (r 0.33, p < 0.01) and TAPSE (r -0.42, p < 0.01) values were proportional to baseline levels. Improvement in PAsP and TAPSE were independent of left ventricular improvements except for PAsP and end-systolic volumes (r 0.44, p < 0.01). Conclusions: In a real world scenario, sacubitril/valsartan was associated with an improved RV function. (C) 2020 The Authors. Published by Elsevier B.V.